Previous close | 15.90 |
Open | 15.85 |
Bid | 0.00 x 12000 |
Ask | 0.00 x 12000 |
Day's range | 15.85 - 15.90 |
52-week range | 15.31 - 49.99 |
Volume | |
Avg. volume | 103 |
Market cap | 1.075B |
Beta (5Y monthly) | 1.69 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
If you want to know who really controls bluebird bio, Inc. ( NASDAQ:BLUE ), then you'll have to look at the makeup of...
The latest analyst coverage could presage a bad day for bluebird bio, Inc. ( NASDAQ:BLUE ), with the analysts making...
Shares of Bluebird Bio (NASDAQ: BLUE) were crashing 23.3% lower as of 12:18 p.m. EDT on Monday. Bluebird said that the U.S. Food and Drug Administration (FDA) has placed a phase 3 study featuring eli-cel (also known as Lenti-D) on clinical hold. The company also stated that it plans to focus only on the U.S. market with its severe genetic disease products and pull out of the European market.